IQVIA™ Real-World Insights Bibliography

Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons
Author(s): Taisuke Ito 1, Kazumasa Kamei 2, Akira Yuasa 3, Fumihiro Matsumoto 2, Yayoi Hoshi 4, Masafumi Okada 4, Shinichi Noto 5 (rwesheorj 4)
Affiliations(s): 1) Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan 2) Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan 3) Health and Value, Pfizer Japan Inc., Tokyo, Japan 4) Real-World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s):  The Journal of Dermatology
Document Type(s): Online article,
Countries: Japan,
Click here for the abstract
C:
Y:
Dermatology, Mental health,
2022
  L:
A:
English
Patient questionnaire, Quality of life, Survey research,
  Add to report
 
 
Factors and their weight in reducing life expectancy in schizophrenia
Author(s): Correll CU, Bitter I, Hoti F, Mehtälä J, Wooller A, Pungor K, Tiihonen J
Affiliations(s): 1.The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA; Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany. Electronic address: ccorrell@northwell.edu. 2.Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. 3.EPID Research, Finland (an IQVIA company). 4.Janssen, Medical Affairs EMEA, High Wycombe, United Kingdom. 5.Janssen-Cilag, Medical Affairs EMEA, Dusseldorf, Germany. 6.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Neuroscience Center, Helsinki, Finland.
Publication(s):  Schizophr Res. 2022 Nov 8;250:67-75.
Document Type(s): Article,
Countries: Finland,
Click here for the abstract
C:
Y:
Mental health,
2022
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study,
  Add to report
 
 
Impact of lurasidone and other antipsychotics on body weight: real-world, retrospective, comparative study of 15,323 adults with schizophrenia
Author(s): Pochiero I, Calisti F, Comandini A, Del Vecchio A, Costamagna I, Rosignoli MT, Cattaneo A, Nunna S, Peduto I, Heiman F, Chang H, Chen C, Correll C
Affiliations(s): Pochiero I: Angelini Regulatory, Research & Development, Angelini Pharma S.p.A., Rome, Italy; Peduto I and Heiman F: IQVIA Solutions Italy Srl, RWS
Publication(s):  Int J Gen Med. 2021 Jul 31;14:4081-4094. doi: 10.2147/IJGM.S320611. PMID: 34366678; PMCID: PMC8336993.
Document Type(s): Article,
Countries: Italy, USA,
Click here for the abstract
C:
Y:
Mental health, Metabolic Disorders ,
2021
  L:
A:
English
Clinical setting: Primary care, Epidemiological study, Retrospective database analysis,
  Add to report
 
 
Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany
Author(s): Kasper S, Bonelli A, Cattaneo A, Comandini A, Di Dato G, Heiman F, Pegoraro V, Palao D, Roca M, Volz HP
Affiliations(s): Kasper S: Center for Brain Research, Medical University of Vienna, Austria; Pegoraro V, Heiman F: IQVIA Solutions Italy S.r.l., RWS
Publication(s):  Int J Psychiatry Clin Pract. 2021 Sep 20:1-10. doi: 10.1080/13651501.2021.1972120. Epub ahead of print. PMID: 34543170.
Document Type(s): Article,
Countries: Germany,
Click here for the abstract
C:
Y:
Mental health,
2021
  L:
A:
English
Clinical setting: Primary care, Epidemiological study, Retrospective database analysis,
  Add to report
 
 
Quantifying the burden of the treatment-resistant depression in Ontario: Shredding light on an inportant mental health issue
Author(s): Brad Millson, G Sarah Power, Dr. Roger S. McIntyre
Affiliations(s): Brad Millson, G Sarah Power, IQVIA RWE team
Publication(s):  CADTH 2020
Document Type(s): Article,
Countries: Canada,
Click here for the abstract
C:
Y:
Health status & patient reported outcomes, Mental health,
2020
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Use of postmenopausal hormone therapy and risk of Alzheimer?s disease in Finland: nationwide case-control study
Author(s): Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS.
Affiliations(s): EPID Research Oy, Espoo, Finland
Publication(s):  BMJ
Document Type(s): Article,
Countries: Finland, Nordic,
Click here for the abstract
C:
Y:
Mental health,
2019
  L:
A:
English
Epidemiological study, Retrospective database analysis,
  Add to report
 
 
Trends in Psychotropic Medication Use for Canadian Children and Youth with ASD from 2010 to 2016: A Pharmacoepidemiologic Study
Author(s): McMorris, C.A.1, Patten, S.2, Stewart, D.3, Tehrani, A.3 & Pringsheim, T.2
Affiliations(s): 1 Werklund School of Education, University of Calgary (Calgary, AB Canada) 2 Cumming School of Medicine, University of Calgary (Calgary, AB Canada)
Publication(s): 
Document Type(s): Poster,
Countries: Canada,
C:
Y:
Mental health,
2019
  L:
A:
English
Database Study,
  Add to report
 
 
Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study
Author(s): Nicholas Cothros1, Davide Martino1, Carly McMorris2,3, David Stewart4, Ali Tehrani4 & Tamara Pringsheim1,5,6*
Affiliations(s): 1Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary and Hotchkiss Brain Institute, Foothills Hospital, Calgary, AB, CA, 2Werklund School of Education, Alberta Children?s Hospital Research Institute (ACHRI), University of Calgary, Calgary, AB, CA, 3The Owerko Centre, Child Development Centre (CDC), Calgary, AB, CA, 4IQVIA, Kanata, ON, CA, 5Department of Psychiatry, Cumming School of Medicine, University of Calgary, Foothills Hospital, Calgary, AB, CA, 6Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, CA
Publication(s):  Tremor Other Hyperkinet Mov (N Y)v.9; 2019
Document Type(s): Article,
Countries: Canada,
Click here for the abstract
C:
Y:
Mental health,
2019
  L:
A:
English
Survey research,
  Add to report
 
 
Comparative Efficacy and Tolerability of Lurasidone versus Other Oral Atypical Antipsychotics for the Treatment of Pediatric Schizophrenia: A Network Meta-Analysis
Author(s): Arango C, Ng-Mak D, Finn E, Byrne A, Rajagopalan K, Loebel A
Affiliations(s): Chair Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, IBERSAM, Madrid, Spain Senior Director, Global Health Economics & Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA QuintilesIMS, London, United Kingdom Head of Global HEOR, Global Health Economics and Outcomes Research, Sunovion Pharmaceuticals, Marlborough, MA Executive Vice President, Chief Medical Officer, Research & Development, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA
Publication(s):  30th Annual U.S. Psych Congress; 2017 Sept 15-19; New Orleans (USA)
European Psychiatric Association; 2018 Mar 3-6; Nice, France.
NEI Congress Scientific Poster Session; 2017 Nov 10; Colorado Springs (USA). Lurasidone in Bipolar Depression: Update of SLR and NMA
Document Type(s): Poster,
Countries: USA,
Click here for the abstract
C:
Y:
Mental health, Pediatrics,
2019
  L:
A:
English
Meta analysis, Retrospective cohort analysis,
  Add to report
 
 
Persistence with Selective Serotonin (Norepinephrine) Reuptake Inhibitor Therapy in Germany
Author(s): Kostev K, Kap EJ
Affiliations(s): IQVIA, Frankfurt am Main, Germany
Publication(s): 
Document Type(s): Abstract,
Countries: Germany,
C:
Y:
Medication compliance, Mental health,
2018
  L:
A:
English
Database Study, Epidemiological study,
  Add to report
 
 
 1 of 25 Next Page Last Page